Innovation for Patients Driven by

The Potential to Forever Change How Cancer is Treated

Allogene Therapeutics is pioneering the development of allogeneic CAR T therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first- generation autologous CAR T therapies to deliver breakthrough clinical benefits, but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.

Learn More

Accelerating an
Expansive Portfolio

We are advancing our allogeneic CAR T cell portfolio acquired from Pfizer, which includes rights to 16 preclinical CAR T cell therapy targets licensed from Cellectis and Servier and U.S. rights to UCART19, an allogeneic CAR T cell therapy candidate that is being developed for the treatment of CD19-expressing hematological malignancies. In partnership with Servier, UCART19 is in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).

Learn More

Led by a Veteran Team

We were co-founded by a team that includes Dr. Arie Belldegrun and Dr. David Chang, who developed one of the first CAR T cell therapies approved by the U.S. Food and Drug Administration. They have unparalleled scientific, clinical and regulatory expertise, and a track record of success.

Learn More

Latest News

Oct 15
2018

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Learn More >
Oct 10
2018

Allogene Therapeutics Announces Pricing of Initial Public Offering

Learn More >
Sep 27
2018

Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors

Learn More >
Sep 14
2018

Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

Learn More >
Sep 06
2018

Allogene Therapeutics Completes a $120 Million Private Financing

Learn More >
Aug 28
2018

Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality August 14, 2018

Learn More >
Aug 14
2018

Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer

Learn More >
Jul 10
2018

Allogene Therapeutics Announces Scientific Advisory Board

Learn More >
Jun 18
2018

Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer

Learn More >
Jun 12
2018

Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports

Learn More >
Jun 04
2018

Allogene Therapeutics Appoints Alison Moore, Ph.D. as Chief Technical Officer

Learn More >
May 30
2018

Allogene Therapeutics Announces Board of Directors

Learn More >
May 14
2018

Allogene Therapeutics Announces Poster Presentation at the Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Learn More >
Apr 09
2018

Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-­oncology Portfolio

Learn More >
Apr 03
2018

Pfizer and Allogene Therapeutics Enter Into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio

Learn More >
Apr 03
2018

Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies

Learn More >